bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
1.730
-0.150 (-7.98%)
At close: Jun 5, 2026, 4:00 PM EDT
1.770
+0.040 (2.31%)
After-hours: Jun 5, 2026, 7:56 PM EDT
bioAffinity Technologies Revenue
bioAffinity Technologies had revenue of $1.35M in the quarter ending March 31, 2026, a decrease of -27.09%. This brings the company's revenue in the last twelve months to $5.66M, down -35.75% year-over-year. In the year 2025, bioAffinity Technologies had annual revenue of $6.16M, down -34.18%.
Revenue (ttm)
$5.66M
Revenue Growth
-35.75%
P/S Ratio
1.39
Revenue / Employee
$99,296
Employees
57
Market Cap
7.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.16M | -3.20M | -34.18% |
| Dec 31, 2024 | 9.36M | 6.83M | 269.68% |
| Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
| Dec 31, 2022 | 4.80K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Inotiv | 507.36M |
| MDxHealth | 110.97M |
| Burning Rock Biotech | 77.14M |
| Exagen | 68.38M |
| XWELL | 28.83M |
| Precipio | 25.83M |
| iSpecimen | 1.03M |
| Quantum Cyber | 537.08K |
BIAF News
- 3 days ago - BioAffinity Technologies announces SAB to host webinar on CyPath Lung - TheFly
- 3 days ago - Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies' Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar - Business Wire
- 9 days ago - BioAffinity Technologies announces notification of Mexico patent allowance - TheFly
- 9 days ago - bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology - Business Wire
- 24 days ago - BioAffinity says CyPath Lung test unit sales achieved monthly record in April - TheFly
- 24 days ago - bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 - Business Wire
- 4 weeks ago - BioAffinity Technologies reports Q1 EPS (81c) vs. ($4.80) last year - TheFly
- 4 weeks ago - bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung - Business Wire